Annual report pursuant to Section 13 and 15(d)

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

v3.5.0.2
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
 12 Months Ended
Apr. 30, 2016
Valuation and Qualifying Accounts [Abstract]  
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

PHARMACYTE BIOTECH, INC.

(FORMERLY NUVILEX, INC.)

SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS

Years Ended April 30, 2016, 2015 and 2014 

 

 

 

Description

   Balance at
Beginning of
Year		   Additions
Charged to
Costs and
Expenses		   Charged to
Other
Accounts		   Deductions   Balance at
End of Year
Reserve Deducted in the Balance Sheets from the Asset to which it applies:                                        
Allowance for Deferred Tax Assets                                        
Year ended April 30, 2016   $ 13,126,337     $ –     $ 3,547,395     $ –     $ 16,673,732  
Year ended April 30, 2015
(As Restated)		   $ 12,821,094     $ –     $ 305,243     $ –     $ 13,126,337  
Year ended April 30, 2014   $ 12,457,023     $ –     $ 364,071     $ –     $ 12,821,094